- Home
- INTU vs SNY Comparison
INTU vs SNY Comparison
Compare INTU & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTU | SNY |
|---|---|---|
| Founded | 1983 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.8B | 104.5B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | INTU | SNY |
|---|---|---|
| Price | $288.65 | $43.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 5 |
| Target Price | ★ $692.35 | $58.00 |
| AVG Volume (30 Days) | ★ 4.8M | 4.2M |
| Earning Date | 05-21-2026 | 04-23-2026 |
| Dividend Yield | 1.22% | ★ 3.47% |
| EPS Growth | ★ 31.06 | N/A |
| EPS | ★ 15.05 | N/A |
| Revenue | ★ $18,831,000,000.00 | N/A |
| Revenue This Year | $15.03 | $3.49 |
| Revenue Next Year | $12.41 | $6.10 |
| P/E Ratio | $18.28 | ★ $6.14 |
| Revenue Growth | ★ 15.63 | N/A |
| 52 Week Low | $252.84 | $40.89 |
| 52 Week High | $813.48 | $52.68 |
Technical Indicators
Market Signals| Indicator | INTU | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 54.42 |
| Support Level | $252.84 | $43.32 |
| Resistance Level | $420.38 | $45.18 |
| Average True Range (ATR) | 10.81 | 0.76 |
| MACD | 5.54 | 0.22 |
| Stochastic Oscillator | 82.02 | 93.18 |
Price Performance
Historical ComparisonAbout INTU Intuit Inc.
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small-to-midsize business accounting and self-serve tax filing in the US.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.